Clinical Trials Related to Acute Myeloid Leukemia

Related studies linked through entity extraction aliases.

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Status: COMPLETED
Phase: PHASE3

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Status: COMPLETED
Phase: PHASE1

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

Status: COMPLETED
Phase: EARLY_PHASE1

Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy

Status: UNKNOWN
Phase: PHASE3

A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia

Status: COMPLETED
Phase: NA

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Status: COMPLETED
Phase: PHASE1

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Status: COMPLETED
Phase: PHASE1

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

Status: TERMINATED
Phase: PHASE1

The Oronasal Microbiota in Pediatric Oncology Patients

Status: COMPLETED
Phase: N/A

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Status: UNKNOWN
Phase: PHASE1/PHASE2

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

Status: TERMINATED
Phase: PHASE2

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Status: COMPLETED
Phase: PHASE2

Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+

Status: COMPLETED
Phase: NA

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Status: UNKNOWN
Phase: PHASE4

Beat AML Core Study

Status: COMPLETED
Phase: N/A

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

Status: COMPLETED
Phase: PHASE4

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Status: COMPLETED
Phase: PHASE3

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia

Status: COMPLETED
Phase: PHASE1

Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Status: COMPLETED
Phase: PHASE1